DISKUS vs. ELLIPTA Device Preference Study in Chronic Obstructive Pulmonary Disease (COPD)

NCT ID: NCT01868009

Last Updated: 2014-03-04

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 287 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-05-31
• Study Completion Date: 2013-07-31

Brief Summary

Subjects who have not used the ELLIPTA™ inhaler nor the DISKUS™ inhaler in the past 6 months will be screened to participate in the study. Subjects will have an equal chance of being in any of the following two groups (1:1 allocation). One group will be dispensed the ELLIPTA inhaler at Visit 1 to use during the first period (once daily for 5 to9 days), and the DISKUS inhaler at Visit 2 to use during the second period (twice daily for 5 to 9 days). The other group will be dispensed the DISKUS inhaler at Visit 1 to use during the first period (twice daily for 5 to 9 days), and the ELLIPTA inhaler at Visit 2 to use during the second period (once daily for 5 to9 days). At the end of the second period, subjects will complete the study by answering 7 questions to assess their preference of device attributes and dosing regimens between the two inhalers.

The null hypothesis for device preference for a specific attribute is that 50% subjects express a preference in that attribute for ELLIPTA and 50% do NOT express a preference in that attribute for ELLIPTA, i.e., the odds for preferring ELLIPTA to not preferring ELLIPTA is unity.

The null hypothesis for dosing regimen preference is that 50% subjects express a preference of once daily dosing and 50% do not express a preference of once daily dosing (prefer twice daily dosing or have no preference).

Conditions

Pulmonary Disease, Chronic Obstructive

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

ELLIPTA Period 1 and DISKUS Period 2 Arm

Subjects will use the ELLIPTA inhaler once daily for 5 to 9 days during the first period followed by the DISKUS inhaler twice daily for 5 to 9 days during the second period.

Group Type: EXPERIMENTAL

ELLIPTA

Intervention Type: DEVICE

Novel dry powder inhaler (placebo) with 30 doses (2 strips with 30 blisters per strip)

DISKUS

Intervention Type: DEVICE

Multidose dry powder inhaler (placebo) containing a foil strip worth 60 blisters (1 strip with 60 blisters per strip)

DISKUS Period 1 and ELLIPTA Period 2 Arm

Subjects will use the DISKUS inhaler twice daily for 5 to 9 days during the first period followed by the ELLIPTA inhaler once daily for 5 to 9 days during the second period.

Group Type: EXPERIMENTAL

ELLIPTA

Intervention Type: DEVICE

Novel dry powder inhaler (placebo) with 30 doses (2 strips with 30 blisters per strip)

DISKUS

Intervention Type: DEVICE

Multidose dry powder inhaler (placebo) containing a foil strip worth 60 blisters (1 strip with 60 blisters per strip)

Interventions

ELLIPTA

Novel dry powder inhaler (placebo) with 30 doses (2 strips with 30 blisters per strip)

Intervention Type: DEVICE

DISKUS

Multidose dry powder inhaler (placebo) containing a foil strip worth 60 blisters (1 strip with 60 blisters per strip)

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• 1. Informed consent
• Subject must give their signed and dated written informed consent to participate.
• Subject understands and is willing, able, and likely to comply with study procedures and restrictions.
• Subject must be able to read, comprehend, and record information in English.
• 2. Age: >=40 years of age at Visit 1
• 3. Gender: Male or female subjects
• 4. COPD diagnosis subjects with a clinical history of COPD in accordance with the definition by the American Thoracic Society/European Respiratory Society
• 5. Severity of disease:
• Subject with a measured post-albuterol Forced expiratory volume in 1 second (FEV1)/ Forced vital capacity (FVC) ratio of <=0.70 at Visit 1
• Subjects with a measured post-albuterol FEV1 <=70% of predicted normal values calculated using Third National Health and Nutrition Examination Survey reference equations at Visit 1.
• Post-bronchodilator spirometry will be performed approximately 10-15 minutes after the subject has self-administered 4 inhalations (i.e., total 400 micrograms) of albuterol via a metered dose inhaler (MDI) with a valved-holding chamber. The FEV1/FVC ratio and FEV1 percent predicted values will be calculated by the investigator site.
• Documented spirometry measurements that meet this criterion in the last 12 months preceding Visit 1 is acceptable.
• 6. Tobacco use: current or former smokers
• Smokers are defined as those who smoke 10 pack-years of cigarette.
• Note: Pipe and/or cigar use cannot be used to calculate pack-year history.
• Number of pack years = (number of cigarettes per day/20) x number of years smoked

Exclusion Criteria

• 1. Previous experience with the DISKUS inhaler
• Subjects who used any DISKUS inhaler (e.g., ADVAIR DISKUS, FLOVENT DISKUS®; participated in a clinical study of fluticasone propionate/salmeterol, or any component of them, or placebo) within 6 months (i.e., 180 days) prior to Visit 1.
• 2. Previous experience with the ELLIPTA inhaler
• Subjects who used any ELLIPTA inhaler (e.g., participated in a clinical study of FF/VI or GSK573719/GW642444 [umeclidinium/vilanterol], or any component of them, or placebo) within 6 months (i.e., 180 days) prior to Visit 1.
• 3. Asthma: Subjects with a current diagnosis of asthma.
• Subjects with a prior history of asthma are eligible if they have a current diagnosis of COPD.
• 4. Poorly controlled COPD: Subjects with symptoms of poorly controlled COPD such as:
• Acute worsening of COPD that is managed by the subject with corticosteroids or antibiotics or that requires treatment prescribed by a physician, in the 4 weeks prior to Visit 1.
• Hospitalization due to acute worsening of COPD within 4 weeks of Visit 1.
• Use of a total of 8 puffs/day or more of short-acting symptom relief medications such as albuterol and ipratropium for 2 consecutive days or any 3 days within 7 days immediately preceding Visit 1.
• Changes in COPD symptoms and signs, suggesting worsening COPD health status at Visit 1.
• 5. Other diseases/abnormalities: Subjects with current evidence of uncontrolled or clinically significant disease.
• Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study.
• Subjects with suspected or evidence of oropharyngeal candidiasis will be excluded from the study.
• Note: subjects who develop oropharyngeal candidiasis during the study will be treated at the discretion of the investigator.
• 6. Drug/food allergy: Subjects with a history of hypersensitivity to any of the components of the inhalation powder (e.g., lactose, magnesium stearate). In addition, subjects with a history of severe milk protein allergy that, in the opinion of the investigator, contraindicates the subject's participation will also be excluded.
• 7. Drug/alcohol abuse: Subjects with a known or suspected alcohol or drug abuse at Visit 1 which in the opinion of the investigator could interfere with the subject's proper completion of the protocol requirement
• 8. Medication prior to spirometry: Subjects who are medically unable or unwilling to withhold their COPD medications prior to spirometry testing at Visit 1. Subjects, who have documented spirometry measurements that meet the specified Inclusion Criterion in the last 12 months preceding Visit 1, do not have to undergo repeat spirometry at Visit 1.
• 9. Investigational drug or device: Subjects who participated in an interventional study or used any investigational drug or device within 30 days or 5 half lives, whichever is longer, prior to Visit 1
• 10. Affiliation with investigator site: Study investigators, sub-investigators, study coordinators, employees of a participating investigator or immediate family members of the aforementioned are excluded from participating in this study.

• Minimum Eligible Age: 40 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

GlaxoSmithKline

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

GSK Investigational Site

Jasper, Alabama, United States

GSK Investigational Site

Riverside, California, United States

GSK Investigational Site

Clearwater, Florida, United States

GSK Investigational Site

Leesburg, Florida, United States

GSK Investigational Site

Orlando, Florida, United States

GSK Investigational Site

Lafayette, Louisiana, United States

GSK Investigational Site

Charlotte, North Carolina, United States

GSK Investigational Site

Huntersville, North Carolina, United States

GSK Investigational Site

Medford, Oregon, United States

GSK Investigational Site

Charleston, South Carolina, United States

GSK Investigational Site

Easley, South Carolina, United States

GSK Investigational Site

Greenville, South Carolina, United States

GSK Investigational Site

Seneca, South Carolina, United States

GSK Investigational Site

Spartanburg, South Carolina, United States

GSK Investigational Site

San Antonio, Texas, United States

GSK Investigational Site

Richmond, Virginia, United States

GSK Investigational Site

Spokane, Washington, United States

Countries

United States

References

Yun Kirby S, Zhu CQ, Kerwin EM, Stanford RH, Georges G. A Preference Study of Two Placebo Dry Powder Inhalers in Adults with COPD: ELLIPTA(R) Dry Powder Inhaler (DPI) versus DISKUS(R) DPI. COPD. 2016;13(2):167-75. doi: 10.3109/15412555.2015.1057274. Epub 2015 Oct 30.

Reference Type: DERIVED

PMID: 26516724 (View on PubMed)

Other Identifiers

116669

Identifier Type: -

Identifier Source: org_study_id